Mawson Infrastructure
MIGI
Digihost Technology
DGHI
Bakkt Holdings
BKKT
Abits
ABTS
Coinbase
COIN
US Stock MarketDetailed Quotes
VTGN VistaGen Therapeutics
- 2.8150
- +0.1150+4.26%
Close Mar 17 16:00 ET
- 2.8500
- +0.0350+1.24%
Post 18:16 ET
81.25MMarket Cap-1.90P/E (TTM)
2.8600High2.6700Low142.28KVolume2.7300Open2.7000Pre Close397.22KTurnover0.70%Turnover RatioLossP/E (Static)28.86MShares5.740052wk High1.00P/B56.93MFloat Cap2.220052wk Low--Dividend TTM20.22MShs Float1889.9991Historical High--Div YieldTTM7.04%Amplitude1.6200Historical Low2.7910Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
VistaGen Therapeutics Stock Forum
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin
Vistagen Receives U.S. Patent for Av-101 to Treat Neuropathic Pain
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Wednesday, 5th February at 8:30 am
Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatmen...
Vistagen Announces Positive Results From Exploratory Phase 2a Study of Ph284 in Cancer Cachexia
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Tuesday, 14th January at 8:30 am
PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients
PH284 is the fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircu...
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Friday, 10th January at 8:30 am
All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in ...
500k shares buy usd3!!
No comment yet